Drugs / Donor derived infection-specific T-cells
Donor derived infection-specific T-cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02843321 | Aug 2012 → Dec 2017 | disease related to hematopoietic stem cell transplant | University of Sydney | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Donor derived infection-specific T-cells | “Donor derived infection-specific T-cells (with activity against CMV,adenovirus, EBV, VZV, Influenza, BKV and Aspergillus)” NCT02843321 ↗ |
| Modality | Cell therapy | “Donor derived infection-specific T-cells” NCT02843321 ↗ |